CliffBio
biologic

Riastap

Fibrinogen Concentrate (Human)

Loss of exclusivityJanuary 2021projected — 12-year biologic exclusivity estimate
CompanyCSL Behring →See this company's full patent-cliff portfolio

Drug detail

Brand nameRiastap
Active ingredientFibrinogen Concentrate (Human)
Strength900-1300MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJanuary 2009
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Riastap patent cliff — loss of exclusivity January 2021 | CliffBio